ABPI response to the NHS England / NICE consultation on technology appraisals and highly specialised technologies.
Commenting on the NHS England and the National Institute for Health and Care Excellence final proposals following consultation on changes to technology appraisals and highly specialised technologies, ABPI Chief Executive, Mike Thompson, said:
"Today's proposals from NICE/NHS England break the Conservative Party's 2015 Manifesto promise to speed up the introduction of cost-effective medicines into the NHS.
No other area of the NHS has the same high levels of scrutiny as medicines. These new plans will prevent patients from receiving NICE approved, cost-effective medicines, undermining their basic rights under the NHS constitution.
Thousands of patients will wait longer for treatment for conditions like heart disease, cancers and diabetes while medicines which stand to benefit the most people are caught up in the system. If the NHS became more effective in its planning it could manage the introduction of new medicines in a coherent way.
Use of new medicines in the UK is already poor with patients seven times more likely to get a newly launched medicine in places like Germany or France. While Scotland and Wales are both making strides in improving the use of new medicines, English patients face more barriers. As we head towards Brexit we should be catching up with Europe not falling further behind.
Just as the Government has today announced it will not break its Manifesto promise on National Insurance, we ask that it also withdraws plans to break its Manifesto promise to NHS patients."
Notes to editors
NHS Scotland has made use of the PPRS payments being made by industry to create a fund to be spent on new medicines approved by the Scottish Medicines Consortium (SMC). The recently published. Montgomery Review has made recommendations to further improve access to medicines in Scotland and has been rapidly endorsed by Scottish Government to be taken forward. These two very positive measures which are unique to Scotland can be expected to help further improve access to medicines north of the border.
The Welsh Government has recently reduced the time taken to provide funding for NICE approved medicines from 90 days to 30 days and this can be expected to have a very positive impact on patient access to new medicines in Wales.
ABPI Press OfficeEmail: firstname.lastname@example.orgTelephone during work hours (9am to 5pm Monday to Friday):+44 (0) 20 7747 7147 or +44 (0) 20 7747 1441Telephone out of hours (5pm to 9am and weekends):+44 (0) 20 7747 1445
About the ABPI
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. We represent companies who supply more than 80 per cent of all branded medicines used by the NHS and who are researching and developing the majority of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome disease.
Globally our industry is researching and developing more than 7,000 new medicines.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry for statutory consultation requirements including the pricing scheme for medicines in the UK.